These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19236201)

  • 1. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure.
    Slawsky MT; Givertz MM
    Expert Opin Pharmacother; 2009 Feb; 10(2):311-22. PubMed ID: 19236201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
    Voors AA; Dittrich HC; Massie BM; DeLucca P; Mansoor GA; Metra M; Cotter G; Weatherley BD; Ponikowski P; Teerlink JR; Cleland JG; O'Connor CM; Givertz MM
    J Am Coll Cardiol; 2011 May; 57(19):1899-907. PubMed ID: 21545947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
    Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
    Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
    Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Weatherley BD; Cleland JG; Givertz MM; Voors A; DeLucca P; Mansoor GA; Salerno CM; Bloomfield DM; Dittrich HC;
    N Engl J Med; 2010 Oct; 363(15):1419-28. PubMed ID: 20925544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure.
    Ensor CR; Russell SD
    Expert Opin Pharmacother; 2010 Oct; 11(14):2405-15. PubMed ID: 20807184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.
    Teerlink JR; Iragui VJ; Mohr JP; Carson PE; Hauptman PJ; Lovett DH; Miller AB; Piña IL; Thomson S; Varosy PD; Zile MR; Cleland JG; Givertz MM; Metra M; Ponikowski P; Voors AA; Davison BA; Cotter G; Wolko D; Delucca P; Salerno CM; Mansoor GA; Dittrich H; O'Connor CM; Massie BM
    Drug Saf; 2012 Mar; 35(3):233-44. PubMed ID: 22339573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of adenosine antagonism in the cardiorenal syndrome.
    Dohadwala MM; Givertz MM
    Cardiovasc Ther; 2008; 26(4):276-86. PubMed ID: 19035879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial.
    Demissei BG; Postmus D; Liu LCY; Cleland JG; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Davison BA; Edwards C; Givertz MM; Bloomfield DM; Dittrich HC; Voors AA; Hillege HL
    Int J Cardiol; 2016 Nov; 223():967-975. PubMed ID: 27589047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function trajectories and clinical outcomes in acute heart failure.
    Givertz MM; Postmus D; Hillege HL; Mansoor GA; Massie BM; Davison BA; Ponikowski P; Metra M; Teerlink JR; Cleland JG; Dittrich HC; O'Connor CM; Cotter G; Voors AA
    Circ Heart Fail; 2014 Jan; 7(1):59-67. PubMed ID: 24281137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study.
    Cleland JG; Chiswell K; Teerlink JR; Stevens S; Fiuzat M; Givertz MM; Davison BA; Mansoor GA; Ponikowski P; Voors AA; Cotter G; Metra M; Massie BM; O'Connor CM
    Circ Heart Fail; 2014 Jan; 7(1):76-87. PubMed ID: 24281134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study.
    Gottlieb SS; Givertz MM; Metra M; Gergich K; Bird S; Jones-Burton C; Massie B; Cotter G; Ponikowski P; Weatherley B; O'Connor C; Dittrich H
    J Card Fail; 2010 Sep; 16(9):714-9. PubMed ID: 20797594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
    Stroh M; Dishy V; Radziszewski W; Hwang E; Lazarus-Shipitofsky N; Dittrich H; Johnson-Levonas AO; Lutz R; Wagner JA; Lai E
    Am J Ther; 2010; 17(1):53-60. PubMed ID: 20027108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine A1 antagonists and the cardiorenal syndrome.
    Gottlieb SS
    Curr Heart Fail Rep; 2008 Jun; 5(2):105-9. PubMed ID: 18765081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function.
    Ponikowski P; Mitrovic V; O'Connor CM; Dittrich H; Cotter G; Massie BM; Givertz MM; Chen E; Murray M; Weatherley BD; Fujita KP; Metra M
    Eur J Heart Fail; 2010 Nov; 12(11):1238-46. PubMed ID: 20823097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
    Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
    J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine A1 receptor antagonists in clinical research and development.
    Hocher B
    Kidney Int; 2010 Sep; 78(5):438-45. PubMed ID: 20592713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute decompensated heart failure and the cardiorenal syndrome.
    Liang KV; Williams AW; Greene EL; Redfield MM
    Crit Care Med; 2008 Jan; 36(1 Suppl):S75-88. PubMed ID: 18158481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
    Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
    Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
    Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
    J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.